What is Network Meta-Analysis?

Network meta-analysis (NMA), also called multiple treatment comparison meta-analysis, allows researchers to compare multiple interventions simultaneously, even if some treatments have never been directly compared in clinical trials. It combines both direct evidence (head-to-head trials) and indirect evidence (through a common comparator) to estimate the relative effectiveness of several treatments.

For example, if studies compare Drug A vs Drug B and Drug B vs Drug C, NMA can estimate Drug A vs Drug C even if no trial directly compared them.

Direct vs Indirect Evidence

Direct evidence comes from trials that directly compare two treatments within the same study. Indirect evidence is derived when two treatments are compared through a shared comparator.

By combining both types of evidence, network meta-analysis increases statistical power and allows researchers to evaluate a larger treatment landscape. However, this requires the assumption that the included studies are sufficiently similar in design and patient population.

Transitivity Assumption

Transitivity is the key assumption behind network meta-analysis. It means that studies comparing different interventions should be similar in terms of patient characteristics, disease severity, and study settings.

If transitivity holds, the indirect comparison between treatments becomes valid. If the assumption is violated, the conclusions from the network meta-analysis may become unreliable.

Ranking of Treatments

One unique advantage of network meta-analysis is that it allows treatments to be ranked according to effectiveness or safety. Methods like SUCRA (Surface Under the Cumulative Ranking Curve) are often used to estimate the probability that a treatment is the best.

This ranking helps clinicians and policymakers decide which treatment may provide the most benefit when several options exist.

Example

Imagine researchers studying treatments for hypertension with three drugs: Drug A, Drug B, and Drug C.

Study 1 compares Drug A vs Drug B

Study 2 compares Drug B vs Drug C

No study compares Drug A vs Drug C

Using network meta-analysis, researchers can estimate the effectiveness of Drug A vs Drug C indirectly through Drug B, and then rank all three drugs according to their performance.

Common Pitfalls and Limitations

Although network meta-analysis is powerful, it can be sensitive to inconsistency and heterogeneity among studies. Differences in patient populations, dosage, or study design may distort indirect comparisons.

Another limitation is that poorly connected networks or small numbers of studies may lead to unstable estimates. Therefore, careful evaluation of study quality and network structure is essential.

Pattern Running (Step-by-Step Workflow)

Define research question and identify multiple interventions.

Conduct a systematic literature search.

Extract data and build a treatment network diagram.

Assess transitivity and study similarity.

Perform statistical network meta-analysis using software (R, STATA, or RevMan extensions).

Evaluate inconsistency and heterogeneity.

Rank treatments using SUCRA or probability ranking.

Interpret results and report according to PRISMA-NMA guidelines.